A Novel Multifunctional Gold Nanorod-mediated and Tumor-targeted Gene Silencing of GPC-3 Synergizes Photothermal Therapy for Liver Cancer
Overview
Authors
Affiliations
Tumor-specific targeted delivery is a major obstacle to clinical treatment of hepatocellular carcinoma (HCC). Here we have developed a novel multi-functional nanostructure GAL-GNR-siGPC-3, which consists of Galactose (GAL) as the HCC-targeting moiety, golden nanorods (GNR) as a framework to destroy tumor cells under laser irradiation, and siRNA of Glypican-3 (siGPC-3) which induce specifically gene silence of GPC-3 in HCC. Glypican-3 (GPC-3) gene is highly associated with HCC and is a new potential target for HCC therapy. On the other hand, Gal can specifically bind to the asialoglycoprotein receptor which is highly expressed on membrane of hepatoma cells. GAL and siGPC-3 can induce targeted silencing of GPC-3 gene in hepatoma cells. In vivo and in vitro results showed that GAL-GNR-siGPC-3 could significantly induce downregulation of GPC-3 gene and inhibit the progression of HCC. More notably, GAL-GNR-siGPC-3 could induce both GPC-3 gene silencing and photothermal effects, and the synergistic treatment of tumors was more effective than individual treatments. In summary, GAL-GNR-siGPC-3 achieved a synergistic outcome to the treatment of cancer, which opens up a new approach for the development of clinical therapies for HCC.
Yang L, Wang H, Li S, Gan G, Deng W, Chang Y World J Gastroenterol. 2024; 30(11):1533-1544.
PMID: 38617449 PMC: 11008421. DOI: 10.3748/wjg.v30.i11.1533.
Liang Y, Wang B, Chen Q, Fu X, Jiang C, Lin Z Theranostics. 2023; 13(15):5452-5468.
PMID: 37908722 PMC: 10614686. DOI: 10.7150/thno.87498.
Gold Nanoparticles: Construction for Drug Delivery and Application in Cancer Immunotherapy.
Huang H, Liu R, Yang J, Dai J, Fan S, Pi J Pharmaceutics. 2023; 15(7).
PMID: 37514054 PMC: 10383270. DOI: 10.3390/pharmaceutics15071868.
The Role of Small Interfering RNAs in Hepatocellular Carcinoma.
Chen F, Zhang W, Gao X, Yuan H, Liu K J Gastrointest Cancer. 2023; 55(1):26-40.
PMID: 37432548 DOI: 10.1007/s12029-023-00911-w.
Triggering Immune System With Nanomaterials for Cancer Immunotherapy.
Li Q, Liu Y, Huang Z, Guo Y, Li Q Front Bioeng Biotechnol. 2022; 10:878524.
PMID: 35497343 PMC: 9046726. DOI: 10.3389/fbioe.2022.878524.